LONARDI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 1.161
EU - Europa 402
AS - Asia 147
AF - Africa 62
Totale 1.772
Nazione #
US - Stati Uniti d'America 1.147
IT - Italia 132
SE - Svezia 96
SG - Singapore 75
GB - Regno Unito 48
CN - Cina 43
DE - Germania 42
CI - Costa d'Avorio 33
BG - Bulgaria 32
VN - Vietnam 16
NG - Nigeria 15
CA - Canada 14
SN - Senegal 13
FI - Finlandia 12
RU - Federazione Russa 12
PL - Polonia 7
FR - Francia 6
HK - Hong Kong 6
CZ - Repubblica Ceca 4
TR - Turchia 4
NL - Olanda 3
AT - Austria 2
GR - Grecia 2
IN - India 2
SK - Slovacchia (Repubblica Slovacca) 2
UA - Ucraina 2
EG - Egitto 1
JP - Giappone 1
Totale 1.772
Città #
Woodbridge 144
Fairfield 129
Chandler 123
Ann Arbor 116
Houston 107
Seattle 54
Ashburn 53
Wilmington 48
New York 46
Cambridge 40
Abidjan 33
Sofia 32
Princeton 28
London 27
Florence 26
Lawrence 26
Medford 20
Ogden 20
Beijing 19
Pisa 18
Serra 18
Singapore 17
Lancaster 16
Lagos 15
Dakar 13
Bremen 11
Ottawa 11
San Diego 11
Dearborn 10
Des Moines 10
Warsaw 7
Hong Kong 6
Verona 6
Düsseldorf 5
Kent 5
Los Angeles 5
Redwood City 5
Rome 5
Dong Ket 4
Frankfurt am Main 4
Nanjing 4
Norwalk 4
Seacroft 4
Boulder 3
Changsha 3
Cislago 3
Detroit 3
Milan 3
Shanghai 3
Shenyang 3
Brno 2
Canino 2
Lappeenranta 2
Marseille 2
Noventa di Piave 2
Phoenix 2
Pistoia 2
Positano 2
Redmond 2
San Giuliano Terme 2
Turin 2
Vicopisano 2
Vienna 2
Washington 2
Amsterdam 1
Berlingo 1
Boardman 1
Bologna 1
Bratislava 1
Cairo 1
Capannori 1
Città della Pieve 1
Council Bluffs 1
Edmonton 1
Gallarate 1
Genoa 1
Guangzhou 1
Hamilton 1
Hangzhou 1
Hanoi 1
Hebei 1
Indore 1
Izmir 1
Jiaxing 1
Kunming 1
Markham 1
Munich 1
Nanchang 1
Rivergaro 1
Rochester 1
Rosignano Marittimo 1
San Francisco 1
Tianjin 1
Tivoli 1
Toronto 1
Torrevecchia Pia 1
Venice 1
Wandsworth 1
Totale 1.388
Nome #
null 129
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 128
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 119
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 117
null 111
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 106
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 96
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 87
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 82
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 81
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 80
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 76
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 61
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 47
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 43
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 39
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 37
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 36
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 36
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 31
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 31
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 30
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 29
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 28
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 24
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 23
Gastric cancer: Translating novels concepts into clinical practice 23
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 22
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 22
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 20
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 17
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 13
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 6
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 5
Totale 1.835
Categoria #
all - tutte 6.896
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.896


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020256 0 12 13 23 38 39 30 25 28 29 13 6
2020/2021116 10 5 5 7 7 3 17 4 14 16 12 16
2021/2022209 2 2 0 6 25 38 5 6 14 22 19 70
2022/2023435 33 76 41 30 49 36 7 24 92 1 38 8
2023/2024253 15 20 43 9 24 42 22 8 7 7 30 26
2024/202511 11 0 0 0 0 0 0 0 0 0 0 0
Totale 1.835